AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9817161 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-GM-CSF
Number of subjects: 28
Study 9817161 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of antibodies to IL-3, IL-5 and GM-CSF
Number of subjects: 28
Study 9817161 — intervention group
Group type: COMPARATOR
Intervention: Eosinophil survival-enhancing activity (ESEA)
Number of subjects: 28
Study 9817161 — intervention group
Group type: COMPARATOR
Intervention: Correlation with eosinophils and CD25(+)CD4 lymphocytes
Number of subjects: 28
Study 8699035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear glucose measurement using Dextrostix (glucose oxidase method)
Number of subjects: 94
Study 8699035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear glucose measurement
Number of subjects: 94
Study 2693162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 and 600 mg daily
Number of subjects: 24
Study 2693162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 356900 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG BFT
Number of subjects: 54
Study 356900 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 54
Study 356900 — intervention group
Group type: EXPERIMENTAL
Intervention: PMR
Number of subjects: 54
Study 356900 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 356900 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 54
Study 31282402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 46
Study 31282402 — intervention group
Group type: COMPARATOR
Intervention: Taekkyon
Number of subjects: 46
Study 29725853 — intervention group
Group type: EXPERIMENTAL
Intervention: Duo (D) implant
Number of subjects: 23
Study 29725853 — intervention group
Group type: EXPERIMENTAL
Intervention: Integra (IN) implant
Number of subjects: 23
Study 29725853 — intervention group
Group type: COMPARATOR
Intervention: Standard geometry, Duo (D), Compact (C), Infra (IF) implants
Number of subjects: 23
Study 29725853 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing time
Number of subjects: 23
Study 29725853 — intervention group
Group type: EXPERIMENTAL
Intervention: ISQ
Number of subjects: 23
Study 27385541 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic plus resistance training (N=97)
Number of subjects: 148
Study 27385541 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (N=51)
Number of subjects: 148
Study 25454337 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 10 sessions over 1 week)
Number of subjects: 24
Study 25454337 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 25454337 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 24
Study 23519639 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of prostate cancer
Number of subjects: 678
Study 23519639 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring after diagnosis
Number of subjects: 678
Study 21802124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily for ≤30 days)
Number of subjects: 136
Study 21802124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg retard daily for ≤30 days)
Number of subjects: 136
Study 21802124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 21802124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (for stones 10-20 mm)
Number of subjects: 136
Study 21802124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (for stones 10-20 mm)
Number of subjects: 136
Study 21802124 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for stones 10-20 mm)
Number of subjects: 136
Study 21802124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 136
Study 21802124 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 136
Study 19406908 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 0.5 mg one IA injection/week for 4 weeks
Number of subjects: 150
Study 19406908 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1 mg one IA injection/week for 4 weeks
Number of subjects: 150
Study 19406908 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 2 mg one IA injection/week for 4 weeks
Number of subjects: 150
Study 19406908 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1 mg two IA injections/week for 2 weeks
Number of subjects: 150
Study 19406908 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) 20 mg one IA injection/week for 4 weeks
Number of subjects: 150
Study 16772320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) 1.5 microg x kg(‐1) x min(‐1)
Number of subjects: 16
Study 16772320 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16
Study 16772320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC)
Number of subjects: 16
Study 12749718 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued smoking after index diagnosis
Number of subjects: 1181
Study 12749718 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued alcohol consumption post-diagnosis
Number of subjects: 1181
Study 12749718 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at diagnosis
Number of subjects: 1181
Study 12749718 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II diagnosis
Number of subjects: 1181
Study 12749718 — intervention group
Group type: EXPERIMENTAL
Intervention: Index diagnosis of pharyngeal cancer
Number of subjects: 1181
Study 10770979 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet (20% of total calories from fat, 18g of dietary fiber per 1000 kcal, 3.5 servings of fruits and vegetables per 1000 kcal)
Number of subjects: 2079
Study 10770979 — intervention group
Group type: COMPARATOR
Intervention: Standard brochure on healthy eating (control group)
Number of subjects: 2079
Study 10770979 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet
Number of subjects: 2079
Study 9594153 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Transient Dearterialization (RTD)
Number of subjects: 40
Study 9594153 — intervention group
Group type: COMPARATOR
Intervention: Hepatic Artery Ligation (HAL)
Number of subjects: 40
Study 1357998 — intervention group
Group type: EXPERIMENTAL
Intervention: LH‐RH plus somatostatin
Number of subjects: 163
Study 1357998 — intervention group
Group type: EXPERIMENTAL
Intervention: LH‐RH
Number of subjects: 163
Study 1357998 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 163
Study 1357998 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 163
Study 1357998 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (combined regimens)
Number of subjects: 163
Study 3993552 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 11
Study 3993552 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 11
Study 3993552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30110008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold tumescence anesthesia solution (4 ℃)
Number of subjects: 51
Study 30110008 — intervention group
Group type: COMPARATOR
Intervention: Room temperature tumescence anesthesia solution (24 ℃)
Number of subjects: 51
Study 27707724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-normoglycemic clamp with AA supplementation
Number of subjects: 20
Study 27707724 — intervention group
Group type: COMPARATOR
Intervention: Hyperinsulinemic-normoglycemic clamp without AA supplementation
Number of subjects: 20
Study 25079064 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 255
Study 25079064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (verteporfin PDT and ranibizumab)
Number of subjects: 255
Study 25079064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 255
Study 22824071 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand curettes
Number of subjects: 30
Study 22824071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalers
Number of subjects: 30
Study 22824071 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 30
Study 20050938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50-100 mg)
Number of subjects: 105
Study 20050938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 18322360 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 40
Study 18322360 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza)
Number of subjects: 40
Study 18322360 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 40
Study 15522858 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of fried foods away from home (highest quintile)
Number of subjects: 37547
Study 15522858 — intervention group
Group type: COMPARATOR
Intervention: Total fat intake
Number of subjects: 37547
Study 15522858 — intervention group
Group type: COMPARATOR
Intervention: Different types of fat and major fatty acids intake
Number of subjects: 37547
Study 11583868 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable troponin T (tnT) levels
Number of subjects: 0
Study 11583868 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of troponin T (tnT)
Number of subjects: 0
Study 11583868 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive arm of the study
Number of subjects: 0
Study 9267791 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Androgen Blockade (TAB) by bilateral orchiectomy and flutamide 250 mg t.i.d.
Number of subjects: 145
Study 9267791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Total Androgen Blockade plus weekly epirubicin 25 mg/m2 i.v. for 18 weeks (E-TAB)
Number of subjects: 145
Study 9267791 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Androgen Blockade (TAB)
Number of subjects: 145
Study 9267791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Total Androgen Blockade plus weekly epirubicin (E-TAB)
Number of subjects: 145
Study 9267791 — intervention group
Group type: EXPERIMENTAL
Intervention: E-TAB in patients with > 5 sites of bone metastasis (D2max)
Number of subjects: 145
Study 9267791 — intervention group
Group type: EXPERIMENTAL
Intervention: TAB in patients with > 5 sites of bone metastasis (D2max)
Number of subjects: 145
Study 9267791 — intervention group
Group type: EXPERIMENTAL
Intervention: E-TAB
Number of subjects: 145
Study 9267791 — intervention group
Group type: COMPARATOR
Intervention: TAB
Number of subjects: 145
Study 7506154 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100mg 3 times daily
Number of subjects: 30
Study 7506154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3101530 — intervention group
Group type: EXPERIMENTAL
Intervention: High branched-chain amino acid formula (11 patients)
Number of subjects: 28
Study 3101530 — intervention group
Group type: EXPERIMENTAL
Intervention: Low branched-chain amino acid formula (9 patients)
Number of subjects: 28
Study 3101530 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 patients, 5% dextrose in water solution)
Number of subjects: 28
Study 3101530 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunostomy groups (High and Low branched-chain amino acid)
Number of subjects: 28
Study 29568790 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric‐psychosomatic consultation with recommendations provided to GPs
Number of subjects: 307
Study 29568790 — intervention group
Group type: COMPARATOR
Intervention: Standard care without psychiatric‐psychosomatic consultation
Number of subjects: 307
Study 27852589 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclacumab 20 mg/kg
Number of subjects: 544
Study 27852589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 24840109 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg daily for 5 days starting on day 5 of menses (Group 1)
Number of subjects: 252
Study 24840109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg daily for 5 days starting the next day after finishing medroxyprogesterone acetate (MPA) (Group 2)
Number of subjects: 252
Study 24840109 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) (Group 2)
Number of subjects: 252
Study 22872647 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg/day
Number of subjects: 72
Study 22872647 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day
Number of subjects: 72
Study 20309947 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Clinical Signs and Symptoms Checklist
Number of subjects: 0
Study 18689159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 18689159 — intervention group
Group type: COMPARATOR
Intervention: Control (no HRT)
Number of subjects: 0
Study 17148514 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoplastic resting splint during weeks 2-3 and weeks 4-7
Number of subjects: 14
Study 17148514 — intervention group
Group type: COMPARATOR
Intervention: No splint during week 2, then wore a splint during week 3, and wore a splint through weeks 4-7
Number of subjects: 14
Study 12825872 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Sigmoidoscopy (FS)
Number of subjects: 20780
Study 12825872 — intervention group
Group type: COMPARATOR
Intervention: Combination of FS and FOBT
Number of subjects: 20780
Study 10713235 — intervention group
Group type: EXPERIMENTAL
Intervention: BSS Plus
Number of subjects: 80
Study 10713235 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 80
Study 10713235 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-temperature BSS Plus
Number of subjects: 80
Study 10713235 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerated fortified BSS Plus
Number of subjects: 80
Study 10713235 — intervention group
Group type: COMPARATOR
Intervention: Modified Ringer's solution
Number of subjects: 80
Study 8806333 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Transluminal Coronary Angioplasty (PTCA)
Number of subjects: 395
Study 8806333 — intervention group
Group type: COMPARATOR
Intervention: Tissue Plasminogen Activator (tPA)
Number of subjects: 395
Study 1353507 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg once a day (n = 26)
Number of subjects: 51
Study 1353507 — intervention group
Group type: COMPARATOR
Intervention: nifedipine sustained-release 20 mg bid (n = 25)
Number of subjects: 51
Study 1353507 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol
Number of subjects: 51
Study 1353507 — intervention group
Group type: COMPARATOR
Intervention: nifedipine
Number of subjects: 51
Study 6426618 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and written antismoking advice from the general practitioner
Number of subjects: 2110
Study 6426618 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus demonstration of exhaled carbon monoxide
Number of subjects: 2110
Study 6426618 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice plus offer of further help from a health visitor
Number of subjects: 2110
Study 6426618 — intervention group
Group type: COMPARATOR
Intervention: Control (non-intervention) group
Number of subjects: 2110
Study 30894212 — intervention group
Group type: EXPERIMENTAL
Intervention: Epacadostat (25, 50, 100, or 300 mg BID; 75 mg daily; or 50 mg BID intermittent) plus ipilimumab 3 mg/kg every 3 weeks
Number of subjects: 50
Study 30894212 — intervention group
Group type: EXPERIMENTAL
Intervention: Epacadostat (various doses) plus ipilimumab
Number of subjects: 50
Study 30894212 — intervention group
Group type: EXPERIMENTAL
Intervention: Epacadostat (≥25 mg BID) plus ipilimumab
Number of subjects: 50
Study 29975061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk
Number of subjects: 19
Study 29975061 — intervention group
Group type: COMPARATOR
Intervention: Rice milk
Number of subjects: 19
Study 29975061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat milk and rice milk
Number of subjects: 19
Study 27757013 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan
Number of subjects: 0
Study 27757013 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan + Dexketoprofen
Number of subjects: 0
Study 24462492 — intervention group
Group type: EXPERIMENTAL
Intervention: Scented condition (pear odour)
Number of subjects: 115
Study 24462492 — intervention group
Group type: COMPARATOR
Intervention: Control condition (non-odorised waiting room)
Number of subjects: 115
Study 23114185 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxostylis alata extract at doses of 100 mg/kg and 200 mg/kg
Number of subjects: 0
Study 23114185 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole at a dose of 60 mg/kg
Number of subjects: 0
Study 19157710 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with a maternal family history of hypertension
Number of subjects: 80
Study 19157710 — intervention group
Group type: COMPARATOR
Intervention: Infants without a maternal family history of hypertension
Number of subjects: 80
Study 17065169 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. remifentanil 1 microg kg(‐1)
Number of subjects: 70
Study 17065169 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline 5 ml (control)
Number of subjects: 70
Study 15547166 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position placement (n = 413)
Number of subjects: 791
Study 15547166 — intervention group
Group type: COMPARATOR
Intervention: Supine position placement (n = 378)
Number of subjects: 791
Study 11868855 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gm/day hydroalcoholic extract of fenugreek seeds
Number of subjects: 25
Study 11868855 — intervention group
Group type: COMPARATOR
Intervention: Usual care (dietary control, exercise) and placebo capsules
Number of subjects: 25
Study 9014542 — intervention group
Group type: COMPARATOR
Intervention: Doxapram (0.18 mg.kg‐1)
Number of subjects: 220
Study 9014542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (0.35 mg.kg‐1)
Number of subjects: 220
Study 8198023 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg every PM for 6 weeks followed by 20 mg twice daily for an additional 6 weeks
Number of subjects: 66
Study 8198023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 3480840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal suppository (2.5 mg PGE2 in Witepsol S55)
Number of subjects: 100
Study 3480840 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of oxytocin
Number of subjects: 100
Study 3480840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal suppository
Number of subjects: 100
Study 30485892 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial extracorporeal liver support (ECLS) systems
Number of subjects: 0
Study 30485892 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume plasma exchange
Number of subjects: 0
Study 30485892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioartificial (cell-based) ECLS systems
Number of subjects: 0
Study 27194403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Plasma-Lyte 148 at 2 mL·kg(‐1) (low volume)
Number of subjects: 150
Study 27194403 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Plasma-Lyte 148 at 20 mL·kg(‐1) (high volume)
Number of subjects: 150
Study 24899558 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical scenario‐based simulation education for communication
Number of subjects: 78
Study 24899558 — intervention group
Group type: COMPARATOR
Intervention: Standard class‐based education for communication
Number of subjects: 78
Study 22108194 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT after FIT
Number of subjects: 3616
Study 22108194 — intervention group
Group type: COMPARATOR
Intervention: First-round FIT
Number of subjects: 3616
Study 20065276 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide inquiries by primary care physicians
Number of subjects: 152
Study 20065276 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of suicide inquiries
Number of subjects: 152
Study 20065276 — intervention group
Group type: EXPERIMENTAL
Intervention: Language used in suicide inquiries
Number of subjects: 152
Study 20065276 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician responses to denial of ideation
Number of subjects: 152
Study 17521473 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium titanyl phosphate laser tonsillectomy
Number of subjects: 80
Study 17521473 — intervention group
Group type: COMPARATOR
Intervention: Bipolar radiofrequency tonsillectomy
Number of subjects: 80
Study 16896786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release chrono VPA (ChVbid, ChVom, ChVoe)
Number of subjects: 48
Study 16896786 — intervention group
Group type: COMPARATOR
Intervention: Conventional VPA (CVbid)
Number of subjects: 48
Study 12831522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (50 mg/kg, as a single dose)
Number of subjects: 165
Study 12831522 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (10 mg/kg twice daily for 5 days)
Number of subjects: 165
Study 12831522 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg/day for 5 days)
Number of subjects: 165
Study 15520757 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed breastfeeding (BF)
Number of subjects: 17046
Study 15520757 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula/other milk
Number of subjects: 17046
Study 15520757 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed BF
Number of subjects: 17046
Study 15520757 — intervention group
Group type: COMPARATOR
Intervention: Cereal intake
Number of subjects: 17046
Study 15520757 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed BF and formula/other milk
Number of subjects: 17046
Study 10724638 — intervention group
Group type: EXPERIMENTAL
Intervention: Monodisperse aerosol (160 micrograms of fenoterol)
Number of subjects: 12
Study 10724638 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI aerosol plus spacer (800 micrograms of fenoterol)
Number of subjects: 12
Study 10724638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7485346 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 209